At a glance
An engineered IGF-I analogue studied for receptor and binding-protein interactions in laboratory systems.
Limits of the evidence. Altered binding-protein affinity does not establish solution stability, shelf life or clinical effects. Material-specific handling and characterization remain separate questions.
Identity and specifications
Long R3 IGF-I has an N-terminal extension and an arginine substitution at position 3 of the IGF-I sequence. It is distinct from native IGF-I.
What the selected studies examined
Francis and colleagues compared recombinant analogues using receptor binding, IGF-binding-protein interactions and responses in cultured cells. Their work examines how different interactions contribute to measured biological activity.
Limitations and open questions
Altered binding-protein affinity does not establish solution stability, shelf life or clinical effects. Material-specific handling and characterization remain separate questions.
These publications describe the materials and experimental conditions used by their authors. They do not establish the identity, composition, stability, safety or performance of East Coast Labs material. A reference list is a selected starting point, not a systematic review.
Interpreting a supplied material
Check the exact product and selected size, then read its documentation status. A laboratory report describes the named sample at the stated date; it does not establish a match to current stock. Read Testing & quality for the distinction between document authenticity and a documented lot relationship.
Handling, solvent compatibility and stability require material-specific information and a validated laboratory protocol. Published biological findings do not establish storage conditions or suitability for a particular experiment.
